Galena Biopharma Inc Stock Nasdaq
Equities
US3632561086
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Apr. 03 | North American Morning Briefing : Powell Awaited -2- | DJ |
Mar. 28 | SELLAS Life Sciences Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 50.61M | Capitalization | 86.65M |
---|---|---|---|---|---|
Net income 2024 * | -40M | Net income 2025 * | -50M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.71 x |
P/E ratio 2024 * |
-1.35
x | P/E ratio 2025 * |
-1.34
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.5% |
Latest transcript on Galena Biopharma Inc
Managers | Title | Age | Since |
---|---|---|---|
Angelos Stergiou
FOU | Founder | 48 | 06-04-02 |
John Burns
DFI | Director of Finance/CFO | 39 | 13-04-30 |
Andrew Elnatan
LAW | General Counsel | - | 23-01-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 17-12-28 | |
David Scheinberg
BRD | Director/Board Member | 68 | 17-11-30 |
John Varian
BRD | Director/Board Member | 64 | 17-12-28 |
1st Jan change | Capi. | |
---|---|---|
-3.10% | 102B | |
+2.11% | 96.07B | |
-1.80% | 21.66B | |
-17.75% | 20.77B | |
-6.91% | 18.53B | |
-42.00% | 16.91B | |
-28.19% | 13.79B | |
+0.18% | 13.33B | |
+19.90% | 10.94B |